[1]杜明亮 郑晓群.心脏淀粉样变性临床研究进展[J].心血管病学进展,2022,(7):636-639,644.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.07.000]
点击复制

心脏淀粉样变性临床研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年7期
页码:
636-639,644
栏目:
综述
出版日期:
2022-07-25

文章信息/Info

Title:
Clinical Research of Cardiac Amyloidosis
文章编号:
202201095
作者:
杜明亮 郑晓群
(大连市中心医院心血管内科,辽宁 大连 116032)
关键词:
心脏淀粉样变性; 限制型心肌病; 诊断
Keywords:
Cardiac amyloidosis;  Restrictive cardiomyopathy;  Diagnosis
DOI:
【DOI】10.16806/j.cnki.issn.1004-3934.2022.07.000
摘要:
心脏淀粉样变性通常表现为限制性的心力衰竭和多浆膜腔积液。心电图表现为肢体低电压、胸导联R波递增不良；在超声心动图上表现为双心房增大，左心室室壁厚度增加，左心室腔不大，左心室舒张功能减退，或有颗粒状心肌强回声等改变；心脏磁共振表现为特征性的心肌延迟强化；组织活检在偏振光显微镜下具有典型的苹果绿双折射和刚果红染色。现通过对心脏淀粉样变性的临床症状及相关实验室结果的讨论，旨在加强临床医师对该疾病的认识。
Abstract:
Cardiac amyloidosis is often manifested as restricted heart failure,multiple serous cavity effusion. Electrocardiogram showed limb low voltage and poor increase of R wave in chest lead. On echocardiography,it showed enlargement of both atria and increased left ventricular wall thickness,small left ventricular cavity,decreased left ventricular diastolic function,changes of granular myocardial strong echo. Cardiac magnetic resonance imaging showed characteristic late gadolinium enhancement. The biopsies showed typical apple green birefringence and Congo red staining under polarized light microscope. In this paper,the clinical symptoms and laboratory results of cardiac amyloidosis are discussed to enhance the understanding of clinicians about this disease

参考文献/References:

[1]Taiwo AA,Alapati L,Movahed A. Cardiac amyloidosis:a case report and review of literature[J]. World J Clin Cases,2019,7(6):742-752.
[2]Ruberg FL,Grogan M,Hanna M,et al. Transthyretin amyloid cardiomyopathy:JACC state-of-the-art review[J]. J Am Coll Cardiol,2019,73(22):2872-2891.
[3]Yilmaz A,Bauersachs J,Bengel F,et al. Diagnosis and treatment of cardiac amyloidosis:position statement of the German Cardiac Society(GDK)[J]. Clin Res Cardiol,2021,110(4):479-506.
[4]Donnelly JP,Hanna M. Cardiac amyloidosis:an update on diagnosis and treatment[J]. Cleve Clin J Med,2017,84(12 suppl 3):12-26.
[5] Benson MD,Buxbaum JN,Eisenberg DS,et al. Amyloid nomenclature 2018:recommendations by the International Society of Amyloidosis(ISA) nomenclature committee[J]. Amyloid,2018,25(4):215-219.
[6] Bistola V,Parissis J,Foukarakis E,et al. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis[J]. Heart Fail Rev,2021,26(4):861-879.
[7] Kocher F,Kaser A,Escher F,et al. Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis[J]. ESC Heart Fail,2020,7(6):3919-3928.
[8] Ablasser K,Verheyen N,Glantschnig T,et al. Unfolding cardiac amyloidosis—From pathophysiology to cure[J]. Curr Med Chem,2019,26(16):2865-2878.
[9] Zhang KW,Stockerl-Goldstein KE,Lenihan DJ. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis[J]. JACC Basic Transl Sci,2019,4(3):438-448.
[10]González-López E,López-Sainz ?,Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope[J]. Rev Esp Cardiol(Engl Ed),2017,70(11):991-1004.
[11] Gertz MA,Benson MD,Dyck PJ,et al. Diagnosis,prognosis,and therapy of transthyretin amyloidosis[J]. J Am Coll Cardiol,2015,66(21):2451-2466.
[12] Lo Presti S,Horvath SA,Mihos CG,et al. Transthyretin cardiac amyloidosis as diagnosed by 99mTc-PYP scanning in patients with acute heart failure and preserved ejection fraction[J]. Crit Pathw Cardiol,2019,18(4):195-199.
[13] Fine NM,Davis MK,Anderson K,et al. Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis[J]. Can J Cardiol,2020,36(3):322-334.
[14] Kapoor M,Rossor AM,Laura M,et al. Clinical presentation,diagnosis and treatment of TTR amyloidosis[J]. J Neuromuscul Dis,2019,6(2):189-199.
[15] Michels da Silva D,Langer H,Graf T. Infammatory and molecular pathways in heart failure-ischemia,HFpEF and transthyretin cardiac amyloidosis[J]. Int J Mol Sci,2019,20(9):2322.
[16] Gertz MA,Dispenzieri A. Systemic amyloidosis recognition,prognosis,and therapy:a systematic reviews[J]. JAMA,2020,324(1):79-89.
[17] Martinez-Naharro A,Hawkins PN,Fontana M. Cardiac amyloidosis[J]. Clin Med(Lond),2018,18(suppl 2):s30-s35.
[18] Grogan M,Dispenzieri A,Gertz MA. Light-chain cardiac amyloidosis:strategies to promote early diagnosis and cardiac response[J]. Heart,2017,103(14):1065-1072.
[19] Hasib Sidiqi M,Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021[J]. Blood Cancer J,2021,11(5):90.
[20] Grogan M,Lopez-Jimenez F,Cohen-Shelly M,et al. Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis[J]. Mayo Clin Proc,2021,96(1):2768-2778.
[21] Alexander KM,Evangelisti A,Witteles RM. Diagnosis and treatment of cardiac amyloidosis related to plasma cell dyscrasias[J]. Cardiol Clin,2019,37(4):487-495.
[22] Hartnett J,Jaber W,Maurer M,et al. Electrophysiological manifestations of cardiac amyloidosis:JACC:CardioOncology?state-of-the-art review[J]. JACC CardioOncol,2021,3(4):506-515.
[23] Boynton SJ,Geske JB,Dispenzieri A,et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2016,9(6):680-686.
[24] Martinez-Naharro A,Baksi AJ,Hawkins PN,et al. Diagnostic imaging of cardiac amyloidosis[J]. Nat Rev Cardiol,2020,17(7):413-246.
[25] Kitaoka H,Izumi C,Izumiya Y,et al. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis[J]. Circ J,2020,84(9):1610-1671.
[26] Garcia-Pavia P,Rapezzi C,Adler Y,et al. Diagnosis and treatment of cardiac amyloidosis:a position statement of the ESC Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J,2021,42(16):1554-1568.
[27] Adam RD,Coriu D,Jercan A,et al. Progress and challenges in the treatment of cardiac amyloidosis:a review of the literature[J]. ESC Heart Fail,2021,8(4):2380-2396.
[28] Palladini G,Milani P,Foli A,et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis[J]. Blood,2017,129(15):2120-2123.
[29] Hegenbart U,Bochtler T,Benner A,et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis:results of a prospective phase 2 study with long-term follow up[J]. Haematologica,2017,102(8):1424-1431.
[30] Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis[J]. Am J Blood Res,2012,2(1):9-17.
[31]Hanna M. Novel drugs targeting transthyretin amyloidosis[J]. Curr Heart Fail Rep,2014,11(1):50-57.
[32]Alexander KM,Singh A,Falk RH. Novel pharmacotherapies for cardiac amyloidosis[J]. Pharmacol Ther,2017,180:129-138.

相似文献/References:

[1]张焰,饶莉.心脏淀粉样变性诊疗进展[J].心血管病学进展,2015,(5):527.[doi:10.3969/j.issn.1004-3934.2015.05.001]
　ZHANG Yan,RAO Li.Advances in Diagnosis and Treatment of Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2015,(7):527.[doi:10.3969/j.issn.1004-3934.2015.05.001]
[2]孙晓昕 方纬 张宇辉.99mTc-焦膦酸盐单光子显像：心脏淀粉样变性分型诊断的新应用[J].心血管病学进展,2023,(1):21.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.006]
　SUN Xiaoxin,FANG Wei,ZHANG Yuhui.99mTc-Pyrophosphate Scintigraphy:New application in Diagnosis and Classification of Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2023,(7):21.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.006]
[3]侯为洁 龚艳君.心脏磁共振在心脏淀粉样变性中的应用进展[J].心血管病学进展,2023,(9):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]
　HOU Weijie,GONG Yanjun.Application of Cardiac Magnetic Resonance in Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2023,(7):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]

备注/Memo

备注/Memo:

通信作者：郑晓群 E-mail：drxiaoqun@163.com

收稿日期：2022-01-22
更新日期/Last Update: 2022-08-22